Literature DB >> 15943758

A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80.

Elizabeth L Gallantine1, Theo F Meert.   

Abstract

delta-Opioid receptor agonists have been postulated to induce analgesia without the adverse effects commonly associated with mu-opioids e.g. morphine. In the present study, we evaluated the occurrence of antinociceptive and opioid-like side effects in rats (n=5-7) treated with a single dose of subcutaneous morphine (0.01 to 40 mg/kg) or SNC80 (0.63 to 80 mg/kg). The antinociceptive effects of morphine and SNC80 were compared using a range of nociceptive tests including the tail withdrawal test, the acetic acid-induced abdominal constriction (writhing) assay, the automated formalin test and a model of inflammation-induced thermal hyperalgesia. The adverse effects of both drugs were examined in animal models for gastrointestinal (GI) inhibition (charcoal test; ricinus oil test), respiratory depression (blood-gas analysis), motor disturbances (automated rotarod model) and abuse liability (drug discrimination learning). Morphine displayed significant antinociceptive and adverse effects in all the animal models employed. SNC80 exhibited a significant effect in the writhing test and limited efficacy in a model of inflammation-induced thermal hypersensitivity. A delay in the occurrence of diarrhoea and some limited increases in PCO(2) were observed with the higher doses of SNC80 (> or =40 mg/kg). In conclusion, the delta-opioid agonist SNC80 lacks both the analgesic efficacy and adverse effects of mu-opioids. However, the activity of SNC80 in the inflammatory model suggests delta-opioid agonists may be useful analgesics in the treatment of some forms of inflammatory pain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15943758     DOI: 10.1111/j.1742-7843.2005.pto_97107.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  49 in total

Review 1.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches.

Authors:  Claire Gavériaux-Ruff; Brigitte Lina Kieffer
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

3.  Exploring the Backbone of Enkephalins To Adjust Their Pharmacological Profile for the δ-Opioid Receptor.

Authors:  Arnaud Proteau-Gagné; Véronique Bournival; Kristina Rochon; Yves L Dory; Louis Gendron
Journal:  ACS Chem Neurosci       Date:  2010-09-17       Impact factor: 4.418

4.  Preparation and evaluation at the delta opioid receptor of a series of linear leu-enkephalin analogues obtained by systematic replacement of the amides.

Authors:  Kristina Rochon; Arnaud Proteau-Gagné; Philippe Bourassa; Jean-François Nadon; Jérome Côté; Véronique Bournival; Fernand Gobeil; Brigitte Guérin; Yves L Dory; Louis Gendron
Journal:  ACS Chem Neurosci       Date:  2013-05-20       Impact factor: 4.418

5.  Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia.

Authors:  L Gendron; J E Pintar; C Chavkin
Journal:  Neuroscience       Date:  2007-10-05       Impact factor: 3.590

6.  Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.

Authors:  Jessica H Harvey; Darcie H Long; Pamela M England; Jennifer L Whistler
Journal:  ACS Med Chem Lett       Date:  2012-08-09       Impact factor: 4.345

7.  Pharmacological Properties of δ-Opioid Receptor-Mediated Behaviors: Agonist Efficacy and Receptor Reserve.

Authors:  Isaac J Dripps; Ruizhuo Chen; Amanda M Shafer; Kathryn E Livingston; Alexander Disney; Stephen M Husbands; John R Traynor; Kenner C Rice; Emily M Jutkiewicz
Journal:  J Pharmacol Exp Ther       Date:  2020-05-28       Impact factor: 4.030

8.  The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors.

Authors:  Isaac J Dripps; Qin Wang; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz
Journal:  Psychopharmacology (Berl)       Date:  2016-09-13       Impact factor: 4.530

9.  δ-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice.

Authors:  Amynah A Pradhan; Monique L Smith; Jekaterina Zyuzin; Andrew Charles
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

10.  In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel mu opioid analgesic with reduced propensity to alter motor function.

Authors:  Mariana Spetea; Catalina R Bohotin; Muhammad F Asim; Kurt Stübegger; Helmut Schmidhammer
Journal:  Eur J Pharm Sci       Date:  2010-06-18       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.